What is the Global market size of the Neuromodulation Devices Market?

Global Neuromodulation Devices Market size was valued at USD 3656.12 million in 2021 and is poised to grow from USD 4000 million in 2022 to USD 8300 million by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

Neuromodulation Devices Market Size, Share, Growth Analysis, By Product (Spinal Cord Stimulators, Deep Brain Stimulators), By Application (E Parkinson’s Disease, Chronic Pain), By End Use (Hospitals & Ambulatory Surgery Centers, Clinics & Physiotherapy Centers), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35A2716 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 93 | Figures: 76

Neuromodulation Devices Market News

In March 2021, Axonics Modulation Technologies, Inc. and Micro Systems Technologies (MST) formed a strategic partnership to produce an implantable sacral neuromodulation device that is not rechargeable.
In March 2021, Helius Medical was given US FDA approval for the Portable Neuromodulation Stimulator, the short-term therapy of multiple sclerosis-related gait impairment.
In January 2021, for its fourth generation Vercise Genus Deep Brain Stimulation (DBS) System, which is used to treat symptoms in individuals with severe Parkinson's disease, Boston Scientific Corporation got FDA approval.

Neuromodulation Devices Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Neuromodulation Devices Market size was valued at USD 5.13 billion in 2022 and is poised to grow from USD 5.58 billion in 2023 to USD 10.87 billion by 2031, growing at a CAGR of 8.7% during the forecast period (2024-2031).

The neuromodulation devices market is highly concentrated, with the top 3–4 companies holding more than 90% of the market. With a varied portfolio, great brand recognition, widespread geographic reach, and a robust distribution network, Medtronic has been able to dominate the industry. Abbott and Boston Scientific Corporation have both experienced a decline in market share over the past few years as a result of delays in the introduction of cutting-edge products in the spinal cord stimulation and other key categories. 'Medtronic ', 'Synapse Biomedical ', 'Abbott Laboratories ', 'Boston Scientific Corporation ', 'LivaNova PLC ', 'Nevro Corp. ', 'NeuroSigma Inc. ', 'NeuroPace Inc. ', 'Cyberonics Inc. ', 'NDI Medical LLC ', 'NeuroMetrix Inc. ', 'NeuroVista Corporation ', 'Neuronetics Inc. ', 'BioControl Medical ', 'SPR Therapeutics ', 'MicroTransponder Inc. ', 'Soterix Medical Inc. ', 'BrainsWay Ltd. ', 'Saluda Medical Pty Ltd '

The global neuromodulation devices market is driven by a number of reasons. One of the key factors propelling the neuromodulation devices market is the increase in health issues. Due to the exceptional capacity to offer comfort in various kinds of illnesses, neuromodulation devices have grown in favor over the years for treating chronic pain, shoulder pain, headaches, and brain injuries. In addition to treating depression, digestive, and sleeping issues, neuromodulation devices are used. Therefore, the business for neuromodulation devices is being driven by the widespread use of these devices to treat a variety of disorders.

A sizable fraction of patients with long-term illnesses, such as chronic back pain, depression, epilepsy, and sleep apnea, among others, are showing signs of drug and medicine resistance. Resistance is evident in the treatment's slow progression and any outcomes that are delayed or insufficient. The market trends for neuromodulation devices are being driven by healthcare practitioners turning their attention to neurostimulation methods for the management of chronic illnesses as a result.

The neuromodulation market size in North America was at its highest level, and the region's dominance is mostly attributable to its patients' higher rates of diagnosis and treatment as well as their greater use of neuromodulation devices to treat chronic illnesses. The second-largest market share belonged to Europe. The demand for these devices is being fueled by a strong healthcare infrastructure as well as an increase in non-invasive device approvals in the region.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Neuromodulation Devices Market News

Neuromodulation Devices Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Neuromodulation Devices Market?

Who are the key vendors in the Neuromodulation Devices Market?

What is the key driver of Neuromodulation Devices Market?

What is the key market trend for Neuromodulation Devices Market?

Which region accounted for the largest share in Neuromodulation Devices Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300